Article
Adults with septic shock and extreme hyperferritinemia exhibit pathogenic immune variation.
Genes and immunity - 1 Jul 2019
Kernan Kate F, Ghaloul-Gonzalez Lina, Shakoory Bita, Kellum John A, Angus Derek C, Carcillo Joseph A
Abstract excerpt
Post-hoc subgroup analysis of the negative trial of interleukin-1β receptor antagonist (IL1RA) for septic shock suggested that patients with features of macrophage activation syndrome (MAS) experienced a 50% relative risk reduction for mortality with treatment. Here we seek a genetic basis for this differential response. From 1341 patients enrolled in the ProCESS trial of early goal directed therapy for septic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
